

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)Dated: February 8, 2001
Nat'l. Entry From: PCT/NO99/00141ATTY DOCKET NO.
1702.401600APPLICATION NO.
09/674,913

APPLICANT

GUSTAV GAUDERNACK, ET AL.

FILING DATE

November 8, 2000GROUP **K647**
Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
<i>GSN</i>	—	WO 98/45322	10/1998	WIPO			Y s
<i>GSN</i>	—	WO 97/12992	4/1997	WIPO			Y s
<i>GSN</i>	—	WO 95/32731	12/1995	WIPO			Yes
<i>GSN</i>	—	WO 92/14756	9/1992	WIPO			Y s
<i>GSN</i>	—	WO 99/58552	11/1999	WIPO			Yes

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>GSN</i>	—	van Leeuwen et al., (1998, January), Science 279:242-247, "Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients"
<i>GSN</i>	—	Vogel, (1998), Science 279:174, "Possible New Cause of Alzheimer's Disease Found"
<i>GSN</i>	—	Gaudernack, (1996), Immunotechnology 2:3-9, "T cell responses against mutant ras: a basis for novel cancer vaccines"
<i>GSN</i>	—	Gjertsen et al. (1996), Int. Joural of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study"
<i>GSN</i>	—	Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4 $^{+}$ and CD8 $^{+}$ T-Lymphocytes, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation"
<i>GSN</i>	—	Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer"

EXAMINER


gkheil

DATE CONSIDERED

11/20/2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 2

FORM PTO 1449 (modified)			ATTY DOCKET NO. 1702.401600	APPLICATION NO. 09/674,913		
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			APPLICANT GUSTAV GAUDERNACK, ET AL.			
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			FILING DATE November 8, 2000	GROUP 164 Unassigned		
Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141						
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
						FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>CJN</i>		Terry et al., Alzheimer Disease, 1994, pp. 179-196, "Structural Basis of the Cognitive Alterations in Alzheimer Disease".				
<i>CJN</i>		Barinaga, Science, vol. 257, 1992, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".				
<i>CJN</i>		Deres et al., Nature, vol. 342, 1989, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".				
<i>CJN</i>		Tighe et al., Immun. Today, vol. 19(2), 1998, pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".				
EXAMINER <i>G. Thielas</i>						
DATE CONSIDERED <i>11/20/2002</i>						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

JWB/NMD/lip